Technical

Stemedica Cell Technologies, Inc., a US company with investment from JZT, received US FDA emergency IND approval for using its bone marrow-derived mesenchymal stem cells to treat severe COVID-19 cases.


Stemedica Cell Technologies, Inc., a US company with investment from JZT, received US FDA emergency IND approval for using its bone marrow-derived mesenchymal stem cells to treat severe COVID-19 cases.